Kronos Bio Halts Phase 2 Trial of Lanraplenib in Leukemia Patients

Kronos Bio has announced that the data from its Phase 1B/2 study of lanraplenib in patients with a specific type of leukemia has led them to halt the trial's progression to Phase 2.

Lanraplenib, one of the key drug candidates from the biopharmaceutical company based in San Mateo, California, had been under investigation alongside gilteritinib for patients suffering from relapsed/refractory FLT3-mutated acute myeloid leukemia.

Reportedly, blast reductions were observed in certain patients; however, there was no complete response among the study participants. Kronos Bio mentioned that a number of patients withdrew from the treatment at an early stage.

Despite this setback, Kronos Bio has unveiled a new development candidate called KB-9558. This candidate specifically targets the lysine acetyltransferase domain of p300, which is recognized as a crucial node within the IRF4 transcription regulatory network. The company asserts that IRF4 is a primary driver in multiple myeloma.

According to Kronos Bio, KB-9558 represents the second molecule to emerge from their proprietary product engine and is currently undergoing IND-enabling studies. These studies are projected to conclude by the fourth quarter of 2024.

Despite this development, Kronos Bio remains confident that its current cash runway will extend until 2026.